Microarray bioinformatics in cancer- a review
|
|
- Edmund Peters
- 6 years ago
- Views:
Transcription
1 JBUON 2017; 22(4): ISSN: , online ISSN: REVIEW ARTICLE Microarray bioinformatics in cancer- a review Ziqi Tao 1, Aimin Shi 2, Rui Li 3, Yiqiu Wang 4, Xin Wang 5, Jing Zhao 6 1 Department of Science and Education, Xuzhou Central Hospital, Xuzhou , China; 2 School of Public Health of Nanjing Medical University, Nanjing , China; 3 Central Laboratory, Xuzhou Central Hospital, Xuzhou , China; 4 Department of Surgical Oncology, Xuzhou Central Hospital, Xuzhou , Jiangsu, China; 5 Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou , Jiangsu, China; 6 Department of Science and Education, Xuzhou Central Hospital, Xuzhou , China Summary Bioinformatics is one of the newest fields of biological research, and should be viewed broadly as the use of mathematical, statistical, and computational methods for the processing and analysis of biological data. Over the last decade, the rapid growth of information and technology in both genomics and omics eras has been overwhelming for the laboratory scientists to process experimental results. Traditional gene-by-gene approaches in research are insufficient to meet the growth and demand of biological research in understanding the true biology. The massive amounts of data generated by new technologies as genomic sequencing and microarray chips make the management of data and the integration of multiple platforms of high importance; this is then followed by data analysis and interpretation to achieve biological understanding and therapeutic progress. Global views of analyzing the magnitude of information are necessary and traditional approaches to lab work have steadily been changing towards a bioinformatics era. Research is moving from being restricted to a laboratory environment to working with computers in a virtual lab environment. The present review article shall put light on this emerging field and its applicability towards cancer research. Key words: bioinformatics, cancer, microarrays Introduction Within the human body, thousands of genes and their products (i.e., RNA and proteins) function in a complicated web and are orchestrated both temporally and spatially. Due to this complexity, the traditional gene-by-gene approach is not powerful enough to define a global view of cellular function. The microarray technology has been designed to measure the activity of gene expression, from the complete genome in a single experiment. Genetic information contained in DNA is consistent with cells of one individual, and a source of variation within and between species [1]. Gene expression, however, varies from tissue to tissue depending on the cell types present in the tissue and its condition (e.g. disease state), giving a source of variation within and between organisms. The ability to measure the expression of multiple genes provides the researcher with a method to elucidate the mechanisms behind this process. Within a couple of years, gene expression microarray technology has developed from profiling a selection of genes on a membrane filter to all mrna transcripts simultaneously (known as a transcriptome ) on a solid surface [2,3]. Current microarrays may have up to tens of thousands of Correspondence to: Ziqi Tao, MD. Department of Science and Education, Xuzhou Central Hospital, 199 Jiefang South Road, Xuzhou, Jiangsu, , China. Tel: , fi778o@163.com Received: 30/01/2017; Accepted: 18/02/2017
2 Microarray bioinformatics in cancer 839 unique DNA sequences spotted to it. The underlying principle of the microarray technology is base-pair hybridization. When using a gene expression microarray, one extracts mrna from the sample of interest, under experimental procedures makes complimentary RNA from this, labels the crna with a fluorescent dye and hybridizes it to a glass slide with the spotted DNA sequences. Sequence specific hybridization ensures that the mrna mostly binds to the DNA from which it is transcribed. Colour intensities for each gene can be quantified from a laser scanner using specialized soft ware for scanning microarrays, which can be used for statistical analysis. Microarray studies with research questions often aim at increasing the knowledge and understanding of gene functions [4]. This is usually done by investigating genes whose expression levels are correlated with experimental conditions or important phenotypes. This could also involve the identification of biological pathways affected by the expression levels of a particular gene, but also in the aspects of drug targets and drug sensitivity in therapy development. Microarray research can also address questions relating to the phenotype of a particular disease. These studies aim at understanding discovering which biological processes are related to certain aspects or subtypes of disease, or identification of disease specific molecular markers. Such information can be of great value in unravelling the complex biological mechanisms involved in a disease. A third direction of microarray research is driven by research questions that relate to the patient. Answers to such questions could potentially improve diagnosis and treatment of disease. Microarrays can be especially useful in prognosis, as future events which are not yet clinically detectable may be predicted through measurement of gene expression activity (such as metastasis in cancer) [5]. Microarray and gene expression in cancer Human cancers are diverse in their tissue of origin as well as their individual biological and genetic histories [6]. These diversities are reflected by variations in gene expression programs among human cancers. Profiling cancer-specific gene expression programs thus may provide a new basis for the classification of human cancers. With the advent of microarray technology, it became possible to analyze and understand cancer-specific gene expression profiles on a global level instead of a gene-by-gene level. Microarray technology is at the heart of this article, with particular focus on gene expression profiling of breast cancers and brain tumors. There are two main reasons for using microarray technology in oncological research. Firstly, to understand the biology related to particular cancer types or subtypes, their gene mutations and their aberrant (downstream) biological pathways. This is largely exploratory and results from a microarray experiment can be analyzed by using pathways and gene annotations such as Gene Ontology. Secondly, to classify human cancers according a particular variable: organ type or subtype, patient s prognosis, prediction of treatment response, or site of metastasis. This can be done in two ways: a) by looking purely at the biology associated with a variable or b) classifying tumors, where the biology of the genes involved is not so important as to have reliable genes that can predict the tested variable [7,8]. These analyses correlate clinical or biological data of cancers with their molecular profiles, in order to identify reliable classifiers. Breast cancer gene expression profiles Perou and Botstein were the first to use microarray technology to study the biology of human cancers by their intrinsic gene expression program [9]. They were able to distinguish several breast cancer subtypes based on gene expression profiles that correlated with previously identified histological protein expression patterns [10,11]. Intrinsic gene signatures were defined that included genes whose differential expression levels could be related to specific histological features of the breast tumors. In a series of follow-up papers, Sorlie and colleagues further refined their intrinsic gene signatures to associate 5 molecular subtypes of breast cancer (Table 1) with survival data of the patients [12-14]. The 5 subtypes defined by these researchers reflect the inherent cell biology that defines the cluster division of the breast cancer subtypes: 1. Luminal A breast cancers expressing estrogen receptors (ER): this subtype is associated with a favourable prognosis. 2. Luminal B breast cancers expressing ER: this subtype has a less favourable prognosis, in particular for relapse of the disease. 3. ERBB2 breast cancers overexpressing ERBB2 and mostly ER negative: this subtype is known for a poor prognosis. 4. Basal-like breast cancers expressing basal cytokeratins 5 and 17, integrin 4 and laminin, but lacking ER, progesterone receptors (PR) and ERBB2 expression: this subtype presents with a more aggressive clinical behaviour. JBUON 2017; 22(4): 839
3 840 Microarray bioinformatics in cancer Table 1. Molecular subtypes of breast cancer Sr. no. Type of cancer Features 1 Luminal A Associated with a favourable prognosis 2 Luminal B It has a less favourable prognosis, in particular for relapse of the disease 3 ERBB2 Overexpressing ERBB2 and mostly ER negative 4 Basal-like Expressing basal cytokeratins 5 and 17, integrin 4 and laminin, but lacking ER, PR and ERBB2 expression This subtype presents with a more aggressive clinical behaviour 5 Normal-like Expressing many genes known to be expressed by adipose tissue and other nonepithelial cell types These tumors also had strong expression of basal epithelial genes and low expression of luminal epithelial genes 5. Normal-like breast cancers, expressing many genes known to be expressed by adipose tissue and other non-epithelial cell types. These tumors also had strong expression of basal epithelial genes and low expression of luminal epithelial genes. Molecular profiles have also been associated with other known cancer genes such as TP53, BRCA1, and EGFR [15-17]. In such studies, the underlying mutation is presumed to be driving the segregation of the samples. Other prominent milestones in the application of gene expression microarrays to breast cancer involve the classification of breast cancers according clinical outcome of the patients. Van t Veer et al. [18] were the first to define a 70-gene expression signature that predicted the occurrence of metastasis in lymph node-negative breast cancer patients who had been diagnosed before 55 years of age. Similarly, a 21-gene signature was shown to predict metastasis in lymph node-negative patients with ER-positive breast cancer who had received adjuvant hormonal therapy [19]. A 76-gene signature also predicted metastasis in lymph node-negative breast cancer patients who had not received any adjuvant systemic therapy, irrespective of age and ER status [20]. Finally, a 44-gene signature has also predicted responsiveness of breast cancers to Tamoxifen therapy more accurate than the ER status of the tumors [21]. The ability of microarray technology to identify breast cancer patients who have a more or less favourable prognosis in developing metastasis could guide clinicians in avoiding adjuvant systemic therapy or, alternatively, to choose more aggressive therapeutic options. In this respect, it could also be useful to predict the site of metastasis, as recently was shown for breast cancers that metastasized to the bone [22]. Brain tumor gene expression profiles Gene expression profiling of brain tumors has been guided primarily by their histological and pathological classification. Brain tumor gene expression profiles have been generated to investigate both the biology and the classification of brain tumors. Looking at biology, Pomeroy et al. [23] defined a gene signature that distinguished medulloblastomas from other histologically similar brain tumors and using this classification could predict their response to therapy. Importantly, this gene signature revealed that medulloblastomas are biologically distinct from primitive neuro-ectodermal tumors (PNETs), two subtypes of brain tumors that are often considered a single entity. The medulloblastoma gene expression profile implicated cerebellar granule cells as their cell of origin and revealed an unexpected involvement of the Sonic Hedgehog signaling pathway. Bredel et al. have also used gene expression profiling in the biological understanding of human gliomas by applying molecular network knowledge to the analysis of key functions and pathways associated with gliomagenesis [24]. Using a set of 50 human gliomas comprised of various histologies, they have seen via the transcriptional profiles of these tumors that integrin signalling pathway is most significant in the glioblastoma subtype, which is paradigmatic for its strong migratory and invasive behaviour. The MYC oncogene was also seen as a major network player in the biological process of gliomagenesis. More specifically, three novel MYC-interacting genes (UBE2C, EMP1, and FBXW7) with cancer-related functions were identified as network constituents differentially expressed in gliomas, as was CD151 as a new component of a network that mediates glioblastoma JBUON 2017; 22(4): 840
4 Microarray bioinformatics in cancer 841 cell invasion [24]. Such biological approaches as Pomeroy et al. and Bredel et al. have extended the existing knowledge about the organizational pattern of gene expression in human gliomas, which can identify potential novel targets for future therapeutic development. Understanding the biology is of utmost importance in brain tumors, however the classification based on its correlation with clinical parameters is also revealing important information. Classification based on histological subtype and genetic mutations as well as clinical parameters such as response to therapeutic drugs can potentially predict a patient s prognosis. French et al. have defined a 16-gene signature that predicted treatment response of oligodendrogliomas and a 103-gene signature for survival of the patients [25]. Interestingly, they were also able to define gene signatures that distinguished oligodendrogliomas with loss of 1p, loss of 19q, or loss of both chromosomal arms. Nutt et al. defined a 20-gene signature that appeared to better predict clinical outcome of patients with glioblastomas or highgrade oligodendrogliomas than classical histology [26]. This gene signature also allowed them to classify high-grade gliomas with non-classical histology. Together, these gene expression-profiling studies have shown that microarray technology may be an important tool in the molecular classification of gliomas. This technology can improve the classification of tumor subgroups as well as the correlation of patient s characteristics to make diagnoses and treatment decisions that are more informed. Perhaps most notable are the findings by French et al. that gene expression profiles not only reflect the biology and clinical behaviour of gliomas but also their underlying molecular basis. Each subtype of glioma is reflected in its pathological and histological characteristics; however, molecular profiles can further distinguish subtypes based on the underlying transcriptome. These molecular profiles are particularly important for brain tumor patients, as they are in urgent need for new treatment targets. Recent applications in the area of oncology In the oncology research field, microarrays are used to study diagnostics as well as the progression of disease and heterogeneity to treatment response. Cancer classifications have primarily been based on the morphological appearance of the tumor, but this has serious limitations, because histopathology is insufficient to predict disease progression and clinical outcome. To overcome this, many research groups have begun to apply microarray technology (Table 2) to identify particular pathological subgroups of disease that can predict patient survival and treatment outcomes. Disease classification not only for cancer has become an important component in downstream microarray analysis. The classification can be divided into two areas: class discovery and class prediction. Class discovery refers to redefining previously unrecognized tumor subtypes and class prediction refers to the assignment of particular tumor samples to the subclass based on a selection of significant genes [27]. Based on this classification, Beer et al. identified a set of genes that can predict survival in early-stage lung carcinoma [28]. This group also described and delineated a high-risk group that may benefit from adjuvant or supplementary therapy, whereby a pharmacological or immunological agent can be added to the treatment to increase or aid its effect or that of the antigenic response. More recently, advanced statistical tools have been applied to these class discovery and predictions in basic research. Multiple myeloma has been studied by numerous cancer research groups using microarray technologies. Claudio et al. confirmed the morphological homogeneity of multiple myeloma [29]. Results from microarray disease classification Table 2. Microarray technology application in cancer Sr. no Name of the technology Applications 1 OmniViz software SAM (Significant Analysis of Microarrays, developed by Stanford) Identification of AML subgroups 2 PAM (Prediction Analysis for Microarrays) 3 Unique combinations of these techniques Identification of class predictors to identify prognostic gene clusters for AML Combinations could predict overall survival among patients within AML subgroups including that with a neutral karyotype AML: acute myeloid leukemia JBUON 2017; 22(4): 841
5 842 Microarray bioinformatics in cancer techniques also established that although multiple myeloma is morphologically homogeneous, there are underlying differences in individual tumor gene expression patterns that correlate with the heterogeneity of disease severity. Such underlying patterns include immunoglobin translocations and other structural genetic changes that both classify and impact patients prognosis of cancer. Golub et al. [27] used sophisticated statistical methods to automatically classify new cases of acute leukaemia into those arising from lymphoid precursors (acute lymphoblastic leukemia) or from myeloid precursors (acute myeloid leukemia [AML]). More specifically and advanced in the area of AML, few studies in the recent past with very large microarray data sets were able to identify subgroups of patients with AML on the basis of molecular signatures and disease classification [30,31]. Using various advanced statistical techniques and visualization tools available today, such as the OmniViz software SAM (Significant Analysis of Microarrays, developed by Stanford) and PAM (Prediction Analysis for Microarrays), they identified 16 subgroups. Genes from these subgroups could be identified as class predictors to identify such prognostically important clusters. These subclasses of AML were featured by various chromosomal lesions such as translocations but also those with normal karyotypes. Some of these unique classes when coupled with extensive clinical data correlated with the prognosis of a poor treatment outcome and could predict overall survival among patients within AML subgroups including that with a neutral karyotype. Conclusion The merging of robotics, biotechnology, and computer sciences, as well as the completion of genome-sequencing efforts for several organisms, has resulted in groundbreaking changes in the way biomedical research is conducted. Biological researchers have traditionally examined functional genetic information to elucidate fundamental cellular processes and unravel the etiology of human disease. In today s post genome era, scientists are drowning in data trying to control high-throughput experimental platforms, and understand the millions of interrelations among proteins, small molecules, and phenotypes. It is now possible to manufacture high density arrays of specified DNA sequences that include every known gene of an organism on a single glass slide. Genomics, informatics, and automation will play increasingly important roles as discovery tools in the basic biological sciences, as well as in diagnostics and therapeutics within the clinical field. Many tools are continually being developed in the microarray field, in both technology and analysis, and the opportunity to apply these technologies to many different fields within bioscience is amazing. Scientists are becoming more aware of microarrays potential to exploit their research, and, as knowledge increases, so do the awareness and possible solutions of the limitations microarrays may currently still hold. Conflict of interests The authors declare no confict of interests. References 1. Masuda M, Yamada T. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. Biochim Biophys Acta 2015;1854: Ewis AA, Zhelev Z, Bakalova R et al. A history of microarrays in biomedicine. Expert Rev Mol Diagn 2005;5: Peeters JK, Van der Spek PJ. Growing applications and advancements in microarray technology and analysis tools. Cell Biochem Biophys 2005;43: Hu N, Wang C, Clifford RJ et al. Integrative genomics analysis of genes with biallelic loss and its relation to the expression of mrna and micro-rna in esophageal squamous cell carcinoma. BMC Genomics 2015;26:16: Kaifi JT, Kunkel M, Das A et al. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. Cancer Biol Ther 2015;16: Marquard AM, Birkbak NJ, Thomas CE et al. Tumor- Tracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen. BMC Med Genomics 2015;8: Wang Y, Klijn J, Zhang Y et al. Gene expression profiles and prognostic markers for primary breast cancer. Meth Mol Biol 2007;377: Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362: Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406: JBUON 2017; 22(4): 842
6 Microarray bioinformatics in cancer Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007;50: Rakha EA, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109: Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98: Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100: Abramovitz M, Leyland-Jones B. A systems approach to clinical oncology: focus on breast cancer. Proteome Sci 2006;4: Voorhoeve PM, le Sage C, Schrier M et al. A genetic screen implicates mirna-372 and mirna-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol 2007;604: Hedenfalk I, Ringner M, Ben-Dor A et al. Molecular classification of familial non-brca1/brca2 breast cancer. Proc Natl Acad Sci U S A 2003;100: Angulo B, Suarez-Gauthier A, Lopez-Rios F et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK- 3CA overexpression by gene amplification. J Pathol 2008;214: Ko JH, Ko EA, Gu W, Lim I, Bang H, Zhou T. Expression profiling of ion channel genes predicts clinical outcome in breast cancer. Mol Cancer 2013;12: van t Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005: 23: Smid M, Wang Y, Klijn JG et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006;24: Jansen MP, Foekens JA, van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005;23: Feng YM, Gao G, Zhang F, Chen H, Wan YF, Li XQ. Identification of the differentially expressed genes between primary breast cancer and paired lymph node metastasis through combining mrna differential display and gene microarray. Zhonghua Yi Xue Za Zhi 2006;86: Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415: Bredel M, Bredel C, Juric D et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC interacting genes in human gliomas. Cancer Res 2005;65: French PJ, Swagemakers SM, Nagel JH et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 200;65: Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63: Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286: Beer DG, Kardia SL, Huang CC et al. Iannettoni MD, Orringer MB, Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8: Claudio JO, Masih-Khan E, Stewart AK. Insights from the gene expression pro Peeters and Van der Spek filing of multiple myeloma. Curr Hematol Rep 2004;3: Bullinger L, Döhner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukaemia. N Engl J Med 2004;350: Valk PJ, Verhaak RG, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350: JBUON 2017; 22(4): 843
RNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationClassification of cancer profiles. ABDBM Ron Shamir
Classification of cancer profiles 1 Background: Cancer Classification Cancer classification is central to cancer treatment; Traditional cancer classification methods: location; morphology, cytogenesis;
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationT. R. Golub, D. K. Slonim & Others 1999
T. R. Golub, D. K. Slonim & Others 1999 Big Picture in 1999 The Need for Cancer Classification Cancer classification very important for advances in cancer treatment. Cancers of Identical grade can have
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationCase Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD
Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD Department of Biomedical Informatics Department of Computer Science and Engineering The Ohio State University Review
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationGene-Expression Profiling and the Future of Adjuvant Therapy
Gene-Expression Profiling and the Future of Adjuvant Therapy Marc van de Vijver Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands Key Words. Gene-expression profiling Prognostic
More informationHarmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief
More informationSupplement 8: Candidate age-related genes and pathways
Supplement 8: Candidate age-related genes and pathways Function Untreated cohort (cohort 1) Treated cohort (cohort 2) Genes Gene sets Effect of age Effect of age FDR of 2 nd Effect of age adjusted Effect
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationConcordance among Gene-Expression Based Predictors for Breast Cancer
The new england journal of medicine original article Concordance among Gene-Expression Based Predictors for Breast Cancer Cheng Fan, M.S., Daniel S. Oh, Ph.D., Lodewyk Wessels, Ph.D., Britta Weigelt, Ph.D.,
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More information30 years of progress in cancer research
Breast Cancer Molecular Knowledge Integrated in Clinical Practice Personalized Medicine Laura J. Esserman UCSF Comprehensive Cancer Center Retreat Breast Cancer Management Advances 80-90s 1) Screening
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationPrognostic implications of the intrinsic molecular subtypes in male breast cancer
JBUON 2017; 22(2): 377-382 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic implications of the intrinsic molecular subtypes in male
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28
More informationModule 3: Pathway and Drug Development
Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7
More informationfor the TCGA Breast Phenotype Research Group
Decoding Breast Cancer with Quantitative Radiomics & Radiogenomics: Imaging Phenotypes in Breast Cancer Risk Assessment, Diagnosis, Prognosis, and Response to Therapy Maryellen Giger & Yuan Ji The University
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationMolecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons
Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationA Biclustering Based Classification Framework for Cancer Diagnosis and Prognosis
A Biclustering Based Classification Framework for Cancer Diagnosis and Prognosis Baljeet Malhotra and Guohui Lin Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada T6G 2E8
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationClinical Oncology - Science in focus - Editorial. Understanding oestrogen receptor function in breast cancer, and its interaction with the
Clinical Oncology - Science in focus - Editorial TITLE: Understanding oestrogen receptor function in breast cancer, and its interaction with the progesterone receptor. New preclinical findings and their
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationGenetic alterations of histone lysine methyltransferases and their significance in breast cancer
Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Supplementary Materials and Methods Phylogenetic tree of the HMT superfamily The phylogeny outlined in the
More informationCommentary The promise of microarrays in the management and treatment of breast cancer Jenny C Chang, Susan G Hilsenbeck and Suzanne AW Fuqua
Commentary The promise of microarrays in the management and treatment of breast cancer Jenny C Chang, Susan G Hilsenbeck and Suzanne AW Fuqua Breast Center, Baylor College of Medicine, Houston, Texas,
More informationProfiles of gene expression & diagnosis/prognosis of cancer Lorena Roa de la Cruz
Genomics Profiles of gene expression & diagnosis/prognosis of cancer Lorena Roa de la Cruz Gene expression profiling Measurement of the activity of thousands of genes at once Techniques used for gene expression
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationModern classification of breast cancer-should we stick with morphology or convert to molecular profiles?
Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationCLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS
CLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS S. Chahbouni¹, A. Amarti 2, N. Hammas 3, L. Chbani 3, H. El fatemi 3 1 Department
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationAward Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.
AD Award Number: W81XWH-08-1-0306 TITLE: Characterizing an EMT Signature in Breast Cancer PRINCIPAL INVESTIGATOR: Melanie C. Bocanegra CONTRACTING ORGANIZATION: Leland Stanford Junior University Stanford,
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationLow levels of serum mir-99a is a predictor of poor prognosis in breast cancer
Low levels of serum mir-99a is a predictor of poor prognosis in breast cancer J. Li 1, Z.J. Song 2, Y.Y. Wang 1, Y. Yin 1, Y. Liu 1 and X. Nan 1 1 Tumor Research Department, Shaanxi Provincial Tumor Hospital,
More informationTITLE: Detection of Genetic Alterations in Breast Sentinel Lymph Node by Array-CGH
AD Award Number: W81XWH-04-1-0671 TITLE: Detection of Genetic Alterations in Breast Sentinel Lymph Node by Array-CGH PRINCIPAL INVESTIGATOR: Luciane R.Cavalli CONTRACTING ORGANIZATION: Georgetown University
More informationCUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationCarcinome du sein Biologie moléculaire. Thomas McKee Service de Pathologie Clinique Genève
Carcinome du sein Biologie moléculaire Thomas McKee Service de Pathologie Clinique Genève Pathology Diagnostic Prognostic information Predictive information The information provided depends on the available
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationDeciphering the Role of micrornas in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma
www.bioinformation.net Volume 13(6) Hypothesis Deciphering the Role of micrornas in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma Ekta Pathak 1, Bhavya 1, Divya Mishra 1, Neelam Atri 1, 2, Rajeev
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationFrom single studies to an EBM based assessment some central issues
From single studies to an EBM based assessment some central issues Doug Altman Centre for Statistics in Medicine, Oxford, UK Prognosis Prognosis commonly relates to the probability or risk of an individual
More informationOutline. Outline. Phillip G. Febbo, MD. Genomic Approaches to Outcome Prediction in Prostate Cancer
Genomic Approaches to Outcome Prediction in Prostate Cancer Phillip G. Febbo, MD Duke Institute for Genome Science and Policy Department of Medicine Department of Molecular Genetics and Microbiology Duke
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationAIMS: Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
AIMS: Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype Eric R. Paquet (eric.r.paquet@gmail.com), Michael T. Hallett (michael.t.hallett@mcgill.ca) 1 1 Department of Biochemistry, Breast
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More informationXXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology
XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology NUEVOS FENOTIPOS DEL CÁNCER DE MAMA: NUEVOS PROBLEMAS PARA EL PATÓLOGO? Tienen actualmente
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationBreast cancer Molecular subtypes and their clinicopathological characteristics amongst patients at the Aga Khan University hospital (Nairobi)
The ANNALS of AFRICAN SURGERY www.sskenya.org Breast cancer Molecular subtypes and their clinicopathological characteristics amongst patients at the Aga Khan University hospital (Nairobi) Gakinya S.M.
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationA REVIEW OF BIOINFORMATICS APPLICATION IN BREAST CANCER RESEARCH
Journal of Advanced Bioinformatics Applications and Research. Vol 1, Issue 1, June 2010, pp 59-68 A REVIEW OF BIOINFORMATICS APPLICATION IN BREAST CANCER RESEARCH Vidya Vaidya, Shriram Dawkhar Department
More informationRare types of breast carcinoma
Open Med. 2015; 10: 92-96 Research Article Open Access Daiva Gudaviciene*, Laura Steponaviciene, Raimundas Meskauskas, Giedre Smailyte, Eduardas Aleknavicius Rare types of breast Abstract: Breast cancer
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
ONCOLOGY REPORTS 21: 413-417, 2009 413 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer HIROKO NOGI 1, TADASHI KOBAYASHI 2, MASAFUMI SUZUKI 3, ISAO TABEI
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationGood Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers q
European Journal of Cancer 40 (2004) 1837 1841 European Journal of Cancer www.ejconline.com Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationMicroarray Analysis and Liver Diseases
Microarray Analysis and Liver Diseases Snorri S. Thorgeirsson M.D., Ph.D. Laboratory of Experimental Carcinogenesis Center for Cancer Research, NCI, NIH Application of Microarrays to Cancer Research Identifying
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationThe Cancer Genome Atlas & International Cancer Genome Consortium
The Cancer Genome Atlas & International Cancer Genome Consortium Session 3 Dr Jason Wong Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 31 st July 2014 1
More informationMODEL-BASED CLUSTERING IN GENE EXPRESSION MICROARRAYS: AN APPLICATION TO BREAST CANCER DATA
International Journal of Software Engineering and Knowledge Engineering Vol. 13, No. 6 (2003) 579 592 c World Scientific Publishing Company MODEL-BASED CLUSTERING IN GENE EXPRESSION MICROARRAYS: AN APPLICATION
More informationCME. CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma
Anatomic Pathology / CK5 vs CK5/6 in Breast Carcinoma CK5 Is More Sensitive Than CK5/6 in Identifying the Basal-like Phenotype of Breast Carcinoma Rohit Bhargava, MD, 1 Sushil Beriwal, MD, 2 Kim McManus,
More informationCase Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
More informationIntroduction to Systems Biology of Cancer Lecture 2
Introduction to Systems Biology of Cancer Lecture 2 Gustavo Stolovitzky IBM Research Icahn School of Medicine at Mt Sinai DREAM Challenges High throughput measurements: The age of omics Systems Biology
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More information